Clinical Trial Update: A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® [Phase 3]

View source ↗

Summary

Phase 3 trial comparing QL1206 with Prolia (denosumab) in postmenopausal women with osteoporosis at high fracture risk; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Prolia (denosumab)
• QL1206 (denosumab)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Postmenopausal Women With Osteoporosis at High Risk of Fracture | Phase 3 | Status: RECRUITING